Details of Disease

Disease Name

Blast phase chronic myelogenous leukemia, BCR-ABL1 positive

blast crises; blast phase; crisis, blast; crises, blast; phase, blast; phases, blast; blast phases; blast phase chronic myeloid leukaemia; blastic phase chronic myelogenous leukaemia; blast phase chronic myelogenous leukaemia; blast phase chronic granulocytic leukaemia; blastic phase chronic granulocytic leukemia; blastic phase chronic myelogenous leukemia; blast crisis; blast phase chronic granulocytic leukemia; blastic phase chronic myeloid leukaemia; blastic phase chronic granulocytic leukaemia; blastic phase chronic myeloid leukemia; blast phase chronic myelogenous leukemia; blastic phase CML; blast phase chronic myeloid leukemia; blast phase chronic myelocytic leukemia; blastic phase chronic myelocytic leukaemia; blast phase chronic myelocytic leukaemia; blastic phase chronic myelocytic leukemia; blast phase CML

Definition

An advanced phase of chronic myelogenous leukemia. It is characterized by: 1. the presence of blasts in the peripheral blood or bone marrow that are at least 20% of the peripheral blood white cells or of the nucleated cells in the bone marrow respectively, or 2. an extramedullary proliferation of blasts, and/or 3. when there are large aggregates and clusters of blasts in the bone marrow biopsy specimen (adapted from WHO, 2001).

Disease Hierarchy

DIS0301E: Chronic myelogenous leukaemia

DIS3KLUX: Blast phase chronic myelogenous leukemia, BCR-ABL1 positive

Disease Identifiers

MONDO ID

MONDO_0006115

MESH ID

D001752

UMLS CUI

C0005699

MedGen ID

2281

SNOMED CT ID

278180008

General Information of Disease (ID: DIS3KLUX)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bosutinib	DMTI8YE	Approved	Small molecular drug	[1]
Dasatinib	DMJV2EK	Approved	Small molecular drug	[2]
Imatinib	DM7RJXL	Approved	Small molecular drug	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 19 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CD33	TTJVYO3	Limited	Altered Expression	[4]
IRF8	TTHUBNK	Limited	Biomarker	[5]
MPL	TTIHYA4	Limited	Biomarker	[6]
CCR7	TT2GIDQ	moderate	Genetic Variation	[7]
CD34	TTZAVYN	moderate	Biomarker	[8]
MTTP	TTUS1RD	moderate	Genetic Variation	[9]
AICDA	TTKRTP6	Strong	Biomarker	[10]
ANPEP	TTPHMWB	Strong	Altered Expression	[11]
BCAT1	TTES57P	Strong	Altered Expression	[12]
FURIN	TTH9WF6	Strong	Biomarker	[13]
HOXA5	TTXSVQP	Strong	Biomarker	[14]
LTB4R2	TTVJX54	Strong	Biomarker	[15]
MKNK1	TTEZAUX	Strong	Biomarker	[16]
MSI2	TTTXQF6	Strong	Altered Expression	[17]
PRAME	TTPH7T0	Strong	Genetic Variation	[18]
TKTL1	TTNQ1J3	Strong	Altered Expression	[19]
CSF3R	TTC70AJ	Definitive	Genetic Variation	[20]
ENPEP	TT9PBIL	Definitive	Biomarker	[21]
SLC25A1	TTTD730	Definitive	Biomarker	[22]
------------------------------------------------------------------------------------


⏷ Show the Full List of 19 DTT(s)

This Disease Is Related to 64 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
A2ML1	OTWNUXIS	Limited	Altered Expression	[23]
ADAR	OTQNOHR8	Limited	Altered Expression	[24]
BACH2	OT17GS18	Limited	Altered Expression	[25]
BRAP	OTB7BAFQ	Limited	Altered Expression	[26]
DDX43	OTK1RYSK	Limited	Biomarker	[27]
FIP1L1	OTF91GTL	Limited	Biomarker	[28]
GATA1	OTX1R7O1	Limited	Genetic Variation	[29]
GATA2	OTBP2QQ2	Limited	Genetic Variation	[30]
IMPA1	OTBUVW1Z	Limited	Altered Expression	[26]
LBR	OT1HG3HG	Limited	Genetic Variation	[31]
POLM	OT0SRIP4	Limited	Altered Expression	[32]
RALGAPB	OTY8CGA3	Limited	Altered Expression	[23]
RBP2	OTR8QG5V	Limited	Altered Expression	[33]
MECOM	OTP983W8	moderate	Genetic Variation	[7]
ARHGEF1	OTXU4HBW	Strong	Biomarker	[34]
ASXL1	OTX931AW	Strong	Biomarker	[35]
ATP5F1E	OTMPLAIS	Strong	Posttranslational Modification	[36]
BCL11B	OT8KKCVJ	Strong	Biomarker	[37]
BCS1L	OT5PY5CY	Strong	Biomarker	[38]
CCNA1	OTX4HD45	Strong	Biomarker	[39]
CDCA7	OT12HDZY	Strong	Altered Expression	[40]
CDCP1	OTD7RRWK	Strong	Altered Expression	[41]
CFC1	OT5DHGI8	Strong	Genetic Variation	[42]
COBLL1	OTQFN1TC	Strong	Biomarker	[43]
CTR9	OTP151PZ	Strong	Altered Expression	[11]
DNTT	OTFSEF12	Strong	Altered Expression	[32]
EBF2	OTFWZE51	Strong	Posttranslational Modification	[44]
ELP1	OTYEWBF7	Strong	Altered Expression	[11]
EN2	OT7EZCM2	Strong	Biomarker	[45]
ESPL1	OTMGEVOK	Strong	Biomarker	[46]
FANCB	OTMZTXB5	Strong	Genetic Variation	[47]
GFI1B	OTRDW8YO	Strong	Altered Expression	[48]
HOXA4	OTNVTQDT	Strong	Biomarker	[14]
HOXA9	OTKNK5H0	Strong	Genetic Variation	[49]
IMMT	OTBDSLE7	Strong	Altered Expression	[50]
LHX4	OTVX3J6S	Strong	Genetic Variation	[51]
MBD2	OTUQPP0R	Strong	Biomarker	[52]
MBNL3	OT2T2YOK	Strong	Biomarker	[53]
NUDCD1	OT8DS3CX	Strong	Biomarker	[54]
NUP98	OTNT12G2	Strong	Genetic Variation	[49]
PACRG	OT1NYNNW	Strong	Genetic Variation	[55]
PCBP2	OTXCN9CG	Strong	Biomarker	[56]
PCNT	OTW4Z65J	Strong	Biomarker	[57]
PIK3R4	OTRL8QP8	Strong	Altered Expression	[11]
PPP2R2B	OTSFVC82	Strong	Altered Expression	[58]
PRDM2	OT8L7CGX	Strong	Altered Expression	[59]
RAB3GAP2	OTQTE0GI	Strong	Altered Expression	[11]
RREB1	OT62460U	Strong	Genetic Variation	[60]
SFTPA1	OT87XL1U	Strong	Biomarker	[61]
SIPA1	OTXY5RXC	Strong	Biomarker	[61]
TBC1D9	OTSSCTB5	Strong	Altered Expression	[62]
BSPH1	OTLLM5JY	Definitive	Biomarker	[63]
EIF3A	OTFABY9G	Definitive	Altered Expression	[64]
GYPB	OTESHUIX	Definitive	Biomarker	[65]
GYPE	OTBHAG6A	Definitive	Biomarker	[65]
MPP1	OTA2ENZQ	Definitive	Biomarker	[66]
PEG10	OTWD2278	Definitive	Biomarker	[67]
POLG2	OTDBMZJB	Definitive	Biomarker	[66]
PSMD12	OTWICA51	Definitive	Biomarker	[66]
RPL22	OTVCN8K0	Definitive	Biomarker	[21]
RTL1	OTOT33IM	Definitive	Biomarker	[67]
RTL3	OT0YJ750	Definitive	Biomarker	[67]
RTL4	OTQE62ZB	Definitive	Biomarker	[67]
SETMAR	OTE2MIMZ	Definitive	Biomarker	[67]
------------------------------------------------------------------------------------


⏷ Show the Full List of 64 DOT(s)

References

1	Bosutinib FDA Label
2	Dasatinib FDA Label
3	Imatinib FDA Label
4	Myeloid/natural killer cell precursor blast crisis of chronic myelogenous leukemia with two Philadelphia (Ph-1) chromosomes.Ann Hematol. 2001 Jan;80(1):58-61. doi: 10.1007/s002770000225.
5	Cross talk between Wnt/-catenin and Irf8 in leukemia progression and drug resistance.J Exp Med. 2013 Oct 21;210(11):2239-56. doi: 10.1084/jem.20130706. Epub 2013 Oct 7.
6	Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy.Blood Adv. 2017 Sep 8;1(20):1729-1738. doi: 10.1182/bloodadvances.2017009530. eCollection 2017 Sep 12.
7	EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.Blood. 2010 Dec 23;116(26):6014-7. doi: 10.1182/blood-2010-01-264234. Epub 2010 Sep 20.
8	Morphine activates blast-phase chronic myeloid leukemia cells and alleviates the effects of tyrosine kinase inhibitors.Biochem Biophys Res Commun. 2019 Dec 10;520(3):560-565. doi: 10.1016/j.bbrc.2019.10.067. Epub 2019 Oct 12.
9	Activation of EVI1 transcription by the LEF1/-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.Biochem Biophys Res Commun. 2017 Jan 22;482(4):994-1000. doi: 10.1016/j.bbrc.2016.11.146. Epub 2016 Nov 28.
10	AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib. Leuk Res. 2011 Oct;35(10):1355-9. doi: 10.1016/j.leukres.2011.04.020. Epub 2011 May 13.
11	ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia.Proc Natl Acad Sci U S A. 2013 Jan 15;110(3):1041-6. doi: 10.1073/pnas.1213021110. Epub 2012 Dec 28.
12	Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia.Nature. 2017 May 25;545(7655):500-504. doi: 10.1038/nature22314. Epub 2017 May 17.
13	Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.Ann Pharmacother. 2013 Nov;47(11):1540-6. doi: 10.1177/1060028013501144. Epub 2013 Nov 21.
14	Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis.Clin Cancer Res. 2007 Sep 1;13(17):5048-55. doi: 10.1158/1078-0432.CCR-07-0919.
15	Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.Biochem Biophys Res Commun. 2016 Apr 15;472(4):610-6. doi: 10.1016/j.bbrc.2016.03.018. Epub 2016 Mar 8.
16	Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.J Med Chem. 2018 May 24;61(10):4348-4369. doi: 10.1021/acs.jmedchem.7b01714. Epub 2018 May 7.
17	RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia.Leuk Res. 2017 Mar;54:47-54. doi: 10.1016/j.leukres.2017.01.015. Epub 2017 Jan 11.
18	Correlation between preferentially expressed antigen of melanoma and tumour necrosis factor-related apoptosis-inducing ligand gene expression in different types of leukaemia patients.Acta Haematol. 2013;130(4):297-304. doi: 10.1159/000351166. Epub 2013 Aug 31.
19	Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML).J Cancer Res Clin Oncol. 2014 Mar;140(3):411-7. doi: 10.1007/s00432-013-1579-x. Epub 2014 Jan 5.
20	Rarity of dominant-negative mutations of the G-CSF receptor in patients with blast crisis of chronic myeloid leukemia or de novo acute leukemia.Leukemia. 1997 Jul;11(7):1005-8. doi: 10.1038/sj.leu.2400697.
21	Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations.Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4004-8. doi: 10.1073/pnas.91.9.4004.
22	Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine.Cancer Chemother Pharmacol. 1988;22(3):205-10. doi: 10.1007/BF00273412.
23	The role of the MDR-1/P-170 mechanism in the development of multidrug resistance in chronic myeloid leukemia.Leukemia. 1990 Oct;4(10):695-9.
24	An RNA editing fingerprint of cancer stem cell reprogramming.J Transl Med. 2015 Feb 12;13:52. doi: 10.1186/s12967-014-0370-3.
25	Transcriptional suppression of BACH2 by the Bcr-Abl oncoprotein is mediated by PAX5.Leukemia. 2013 Feb;27(2):409-15. doi: 10.1038/leu.2012.220. Epub 2012 Aug 3.
26	Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis.Anticancer Res. 1996 Nov-Dec;16(6A):3349-51.
27	The methylation status of the DDX43 promoter in Chinese patients with chronic myeloid leukemia.Genet Test Mol Biomarkers. 2013 Jun;17(6):508-11. doi: 10.1089/gtmb.2012.0530. Epub 2013 Mar 15.
28	Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis.Exp Hematol. 2014 May;42(5):369-379.e3. doi: 10.1016/j.exphem.2014.01.009. Epub 2014 Jan 31.
29	GATA1 mutational analysis in chronic myeloid leukaemia.Br J Haematol. 2007 May;137(4):375-6. doi: 10.1111/j.1365-2141.2007.06563.x. Epub 2007 Apr 4.
30	Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia.Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2076-81. doi: 10.1073/pnas.0711824105. Epub 2008 Feb 4.
31	A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.Haematologica. 2015 Jul;100(7):898-904. doi: 10.3324/haematol.2014.115279. Epub 2015 Apr 17.
32	Relation of "lymphoid" phenotype and response to chemotherapy incorporating vincristine-prednisolone in the acute phase of Ph1 positive leukemia.Cancer. 1979 Feb;43(2):426-34. doi: 10.1002/1097-0142(197902)43:2<426::aid-cncr2820430204>3.0.co;2-h.
33	Histone demethylase RBP2 mediates the blast crisis of chronic myeloid leukemia through an RBP2/PTEN/BCR-ABL cascade.Cell Signal. 2019 Nov;63:109360. doi: 10.1016/j.cellsig.2019.109360. Epub 2019 Jul 30.
34	Chronic myeloid leukemia stem cells.Hematology Am Soc Hematol Educ Program. 2008:436-42. doi: 10.1182/asheducation-2008.1.436.
35	RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.J Hematol Oncol. 2019 Oct 22;12(1):104. doi: 10.1186/s13045-019-0789-3.
36	Down-regulation of mitochondrial ATPase by hypermethylation mechanism in chronic myeloid leukemia is associated with multidrug resistance.Ann Oncol. 2010 Jul;21(7):1506-1514. doi: 10.1093/annonc/mdp569. Epub 2009 Dec 27.
37	Haploinsufficiency and acquired loss of Bcl11b and H2AX induces blast crisis of chronic myelogenous leukemia in a transgenic mouse model.Cancer Sci. 2009 Jul;100(7):1219-26. doi: 10.1111/j.1349-7006.2009.01172.x. Epub 2009 Apr 21.
38	MLL-PTD in a 13-year-old patient with blast phase myeloproliferative neoplasm: A case report.Medicine (Baltimore). 2018 Nov;97(46):e13220. doi: 10.1097/MD.0000000000013220.
39	The proto-oncogene expression varies over the course of chronic myeloid leukemia.Hematology. 2008 Feb;13(1):34-40. doi: 10.1179/102453308X315807.
40	The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivo.Cancer Res. 2005 Jul 1;65(13):5620-7. doi: 10.1158/0008-5472.CAN-05-0536.
41	CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin.Stem Cells. 2004;22(3):334-43. doi: 10.1634/stemcells.22-3-334.
42	Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript.Eur J Haematol. 2016 Oct;97(4):399-402. doi: 10.1111/ejh.12752. Epub 2016 Mar 26.
43	Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia.Leukemia. 2017 Jul;31(7):1532-1539. doi: 10.1038/leu.2017.72. Epub 2017 Feb 24.
44	A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers.Mol Cancer. 2010 Feb 25;9:44. doi: 10.1186/1476-4598-9-44.
45	Lineage-specific function of Engrailed-2 in the progression of chronic myelogenous leukemia to T-cell blast crisis.Cell Cycle. 2014;13(11):1717-26. doi: 10.4161/cc.28629. Epub 2014 Mar 25.
46	Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.PLoS One. 2015 Jun 18;10(6):e0129648. doi: 10.1371/journal.pone.0129648. eCollection 2015.
47	Inversion of chromosome 16 in accelerated phase of chronic myeloid leukaemia: report of a case and review of the literature.Med Oncol. 1998 Sep;15(3):199-201. doi: 10.1007/BF02821939.
48	Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.Cancer Gene Ther. 2013 Jul;20(7):421-7. doi: 10.1038/cgt.2013.31. Epub 2013 Jun 21.
49	NUP98-HOXA9-transgenic zebrafish develop a myeloproliferative neoplasm and provide new insight into mechanisms of myeloid leukaemogenesis.Br J Haematol. 2011 Oct;155(2):167-81. doi: 10.1111/j.1365-2141.2011.08810.x. Epub 2011 Aug 2.
50	Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance.Cell Cycle. 2006 Oct;5(19):2223-9. doi: 10.4161/cc.5.19.3255. Epub 2006 Oct 1.
51	Aberrant expression of the LHX4 LIM-homeobox gene caused by t(1;14)(q25;q32) in chronic myelogenous leukemia in biphenotypic blast crisis.Genes Chromosomes Cancer. 2003 Nov;38(3):269-73. doi: 10.1002/gcc.10283.
52	Deletion of MBD2 inhibits proliferation of chronic myeloid leukaemia blast phase cells.Cancer Biol Ther. 2018 Aug 3;19(8):676-686. doi: 10.1080/15384047.2018.1450113. Epub 2018 Apr 19.
53	Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal.Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15444-9. doi: 10.1073/pnas.1506943112. Epub 2015 Nov 30.
54	Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells.Clin Cancer Res. 2005 Jun 15;11(12):4504-11. doi: 10.1158/1078-0432.CCR-05-0036.
55	Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia.Int J Cancer. 2006 Apr 15;118(8):1945-53. doi: 10.1002/ijc.21584.
56	miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.Cell. 2010 Mar 5;140(5):652-65. doi: 10.1016/j.cell.2010.01.007.
57	Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability.Leukemia. 2005 Jul;19(7):1192-7. doi: 10.1038/sj.leu.2403779.
58	The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.Cancer Cell. 2005 Nov;8(5):355-68. doi: 10.1016/j.ccr.2005.10.015.
59	RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression.J Hematol Oncol. 2009 Jul 14;2:28. doi: 10.1186/1756-8722-2-28.
60	Whole-genome analysis reveals unexpected dynamics of mutant subclone development in a patient with JAK2-V617F-positive chronic myeloid leukemia.Exp Hematol. 2017 Sep;53:48-58. doi: 10.1016/j.exphem.2017.05.007. Epub 2017 Jun 8.
61	Myeloproliferative stem cell disorders by deregulated Rap1 activation in SPA-1-deficient mice.Cancer Cell. 2003 Jul;4(1):55-65. doi: 10.1016/s1535-6108(03)00163-6.
62	Multidrug resistance in leukemias and its reversal.Leuk Lymphoma. 1996 Nov;23(5-6):451-8. doi: 10.3109/10428199609054853.
63	Basophils (Bsp-1+) derive from the leukemic clone in human myeloid leukemias involving the chromosome breakpoint 9q34.Blood. 1989 Feb 15;73(3):777-81.
64	Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3.Blood. 1998 Mar 1;91(5):1700-5.
65	Erythroid blast crisis in chronic myelogenous leukemia.Blood. 1983 Sep;62(3):591-6.
66	Exon skipping truncates the PDZ domain of human erythroid p55 in a patient with chronic myeloid leukemia in acute megakaryoblastic blast crisis.Leuk Res. 1999 Mar;23(3):247-50. doi: 10.1016/s0145-2126(98)00164-7.
67	Emergence of a cell line with extreme hypodiploidy in blast crisis of chronic myelocytic leukemia.Blood. 1979 Apr;53(4):707-11.